Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $14.67.
Several research analysts have recently issued reports on IVA shares. Wall Street Zen upgraded shares of Inventiva from a "sell" rating to a "hold" rating in a report on Saturday, October 3rd. Truist Financial boosted their target price on shares of Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, October 2nd. HC Wainwright dropped their target price on shares of Inventiva to $14.00 and set a "buy" rating on the stock in a report on Thursday, November 5th. Guggenheim boosted their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Finally, Weiss Ratings downgraded Inventiva from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, November 13th.
Check Out Our Latest Report on Inventiva
Inventiva Stock Performance
IVA opened at $3.45 on Friday. The firm's 50-day moving average price is $3.54 and its 200 day moving average price is $4.70. Inventiva has a twelve month low of $2.82 and a twelve month high of $7.29.
Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million for the quarter. As a group, sell-side analysts predict that Inventiva will post -0.75 earnings per share for the current year.
Institutional Investors Weigh In On Inventiva
Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its stake in shares of Inventiva by 64.2% in the third quarter. Goldman Sachs Group Inc. now owns 368,669 shares of the company's stock worth $1,360,000 after purchasing an additional 144,170 shares during the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of Inventiva during the 3rd quarter valued at approximately $306,000. Marshall Wace LLP boosted its stake in Inventiva by 134.2% during the third quarter. Marshall Wace LLP now owns 2,262,530 shares of the company's stock worth $8,349,000 after buying an additional 1,296,623 shares during the period. Nantahala Capital Management LLC increased its position in shares of Inventiva by 11.9% during the third quarter. Nantahala Capital Management LLC now owns 3,004,859 shares of the company's stock worth $11,088,000 after acquiring an additional 318,466 shares during the period. Finally, Aberdeen Group plc boosted its position in Inventiva by 36.3% during the 3rd quarter. Aberdeen Group plc now owns 3,145,711 shares of the company's stock valued at $11,608,000 after acquiring an additional 837,938 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company's stock.
Inventiva Company Profile
(
Get Free Report)
Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.